SUMMIT is an open-label, single-arm, multi-cohort, phase 2, ‘basket’ trial of neratinib in patients with solid tumours harbouring oncogenic HER2 somatic mutations (ClinicalTrials.gov: NCT01953926)....Neratinib was well tolerated and showed antitumour activity in patients with metastatic gallbladder cancer or cholangiocarcinoma harbouring HER2 mutations.